Summary
Medtronic might see a significant drop in its sales as a result of closer scrutiny of off-label use of its products. Infuse has been a cash cow for Medtronic, and if sales drop, it will reflect deeply in the sales numbers.
Analysis
Medtronic is a juggernaut in the spine industry, but they have lost market share in the device implant section due to strong competition. They have been able to weather the storm through sales of Infuse, a bone morphogenic protein widely used for spinal fusions.
If the Feds actions intimidate the surgeons into using the product strictly under the FDA approval indications, then sales might actually drop by 20-40%.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
